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Dorsal	root	ganglion	(DRG)	neuron	dysfunction	occurs	in	a	variety	of	sensory	neuronopathies	for	which	there	
are	currently	no	satisfactory	treatments.	Here	we	describe	the	development	of	a	strategy	to	target	therapeutic	
genes	to	DRG	neurons	for	the	treatment	of	these	disorders.	We	genetically	modified	an	adenovirus	(Ad)	to	gen-
erate	a	helper	virus	(HV)	that	was	detargeted	for	native	adenoviral	tropism	and	contained	DRG	homing	pep-
tides	in	the	adenoviral	capsid	fiber	protein;	we	used	this	HV	to	generate	DRG-targeted	helper-dependent	Ad	
(HDAd).	In	mice,	intrathecal	injection	of	this	HDAd	produced	a	100-fold	higher	transduction	of	DRG	neurons	
and	a	markedly	attenuated	inflammatory	response	compared	with	unmodified	HDAd.	We	also	injected	HDAd	
encoding	the	β	subunit	of	β-hexosaminidase	(Hexb)	into	Hexb-deficient	mice,	a	model	of	the	neuronopathy	
Sandhoff	disease.	Delivery	of	the	DRG-targeted	HDAd	reinstated	neuron-specific	Hexb	production,	reversed	
gangliosidosis,	and	ameliorated	peripheral	sensory	dysfunction.	The	development	of	DRG	neuron–targeted	
HDAd	with	proven	efficacy	in	a	preclinical	model	may	have	implications	for	the	treatment	of	sensory	neu-
ronopathies	of	diverse	etiologies.
Introduction
Dysfunction of neurons in dorsal root ganglion (DRG) occurs in a 
variety of sensory neuronopathies (1, 2), including hereditary (3), 
autoimmune (4), nutritional (5), metabolic (6), and neoplastic dis-
eases (7). DRG neuronal disorders are notoriously difficult to treat 
and are a common cause of much pain and suffering in the form 
of neuropathic pain, loss of sensation, and sensory ataxia (1, 2). 
Treatments that specifically target DRG neurons would be ideal. 
Unfortunately, the development of DRG-targeted therapy has been 
challenging (1, 2). Delivery of neurotrophic factors can minimize 
neuronal damage in the DRG (8). However, neurotrophic polypep-
tides are susceptible to proteolytic degeneration, and their thera-
peutic effects are short-lived; direct delivery of therapeutic genes 
proves to be more effective (9, 10). Herpes simplex virus (9) and 
poliovirus (11) injected through subcutaneous or intramuscular 
routes are taken up by endocytosis at nerve terminals, and some 
will travel via axonal transport to somas of DRG neurons. To fur-
ther increase the efficiency of gene delivery, direct injection into 
DRG neurons by microneurosurgery can be accomplished by the 
removal of a piece of vertebra to gain access to the DRG (12, 13). 
However, such a maneuver is not practical for repeated injections, 
which is likely required for chronic disorders. In contrast, intrathe-
cal (i.t.) injection is a far less invasive procedure that is used rou-
tinely in clinical practice (10). Nevertheless, DRG are ensheathed 
in the dura and bathed in cerebrospinal fluid (CSF). Gene delivery 
vectors could disperse and be taken up elsewhere, leading to com-
plications, including meningitis (14). To optimize the chance for 
successful DRG neuron delivery while minimizing undesired off-
target effects, targeted gene delivery would be an ideal strategy for 
delivering genes to DRG neurons (15).
Adenovirus (Ad) is an efficient gene transfer system in vitro 
as well as in vivo because of its capacity to infect both quiescent 
and proliferating cells, its broad spectrum of tissue transduction 
susceptibility, and the relative ease with which the vector can be 
produced in high titer. Helper-dependent Ad (HDAd) is the most 
advanced Ad, devoid of all viral coding sequences. The lack of 
potentially harmful Ad viral gene expression is associated with 
markedly reduced toxicity. HDAd-mediated in vivo gene delivery 
in rodents and nonhuman primates has been found to have an 
excellent safety profile and protracted transgene expression (16, 
17). Other advantages of HDAd are a large cloning capacity, up to 
37 kb, and a greatly attenuated adaptive host immune response 
(18). For these reasons, we selected HDAd as the backbone for the 
targeted vector for DRG neuron delivery.
The cellular tropism of Ad serotype 5 (Ad5) is determined by the 
cell surface expression of primary attachment sites coxsackie and 
adenovirus receptor (CAR; refs. 19, 20) and heparan sulfate proteo-
glycans (HSPGs; refs. 21–23). Integrins act as secondary internaliza-
tion receptors (21, 24, 25). Cells deficient in the expression of these 
receptors are transduced with greatly reduced efficiency. Little or 
no CAR is expressed by DRG neurons, which are poor targets for 
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unmodified Ads (26). Considerable effort has been expended on 
the generation of first-generation Ads that target normally refrac-
tory tissues and retarget to alternative cell type–specific receptors. 
The 3 major strategies currently used are genetic modification 
of Ad capsid proteins; conjugation of adaptor proteins, such as 
antibody or bispecific fusion proteins; and chemical modification 
by polymers with targeting ligands (15, 27). Genetic modification 
appears to the most popular of these approaches. This technol-
ogy is particularly appealing for HDAd because capsid proteins of 
HDAd are supplied by the helper virus (HV). Armed with a library 
of targeting HVs, one can produce HDAds that potentially target 
any tissue by applying the specific HV at the final amplification. 
To date, despite the many potential advantages of HDAds, target-
ing HDAds by genetic modification has been limited to the intro-
duction of peptide ligands into the HI loop (28) or replacement of 
fiber gene with that of a different Ad serotype (29).
We report here a strategy to engineer fiber-modified HDAd and 
demonstrated the efficacy of HDAd bearing DRG neuron–specific 
targeting peptide (30) to correct a genetic deficiency and reverse its 
associated sensory deficit in a mouse model (31, 32). We introduced 
targeting ligands into the fiber of HV possessing mutated fiber pro-
teins to avoid native Ad tropism and showed that these fiber-delet-
ed HV possessed markedly impaired ability to transduce 293 cells 
and DRG neurons in vitro. Moreover, the addition of DRG target-
ing peptide ligands efficiently retargeted HV to DRG neurons. In 
addition, using Cre-expressing HDAd amplified in the presence of 
fiber-modified HVs, we documented high-efficiency DRG neuron 
targeting in vivo after i.t. injection into ROSA-GFP transgenic mice. 
Finally, we demonstrated the efficacy of the targeting strategy to 
correct a genetic deficiency in DRG neurons, reversing specifically 
the peripheral sensory nervous system dysfunction in mice with 
β-hexosaminidase deficiency. We suggest that this strategy, which 
we believe to be novel, could fill an immediate need in applying 
targeted HDAd gene therapy for DRG neuron disorders.
Results
Production of fiber-modified HV. In a much-used method for HDAd 
production, all necessary factors for packaging HDAd genome are 
supplied in trans by a HV, a first-generation Ad. In this scheme, 
HDAd that expresses the gene of interest (e.g., a therapeutic trans-
gene) can be made to target a specific organ or cell type simply by 
using an appropriate HV at the final amplification (33) — there 
is no need to engineer a new HDAd (Supplemental Figure 1; sup-
plemental material available online with this article; doi:10.1172/
JCI39038DS1). To produce targeted HV, we first attenuated the 
natural tropism by ablating the binding sites of Ad5 fiber to ame-
liorate binding to primary receptors 
(KO1S* mutation; refs. 34, 35). To 
circumvent the very poor infectivity 
of this KO1S* mutant Ad toward 293 
cells, we established 293 cells express-
ing Ad5 wild-type fiber (referred to 
herein as 293-fiber cells) to incor-
porate wild-type fiber (WF) into the 
capsid of HV-KO1S* (Supplemental 
Figure 3A). Fiber-modified HV gener-
ated on 293-fiber cells had both WF 
and modified fiber encoded by HV 
genome. We generated a total of 5 
HVs: HV-WF; HV-KO1S*, a detargeted 
HV; and 3 HVs on a HV-KO1S* backbone that contain individual 
DRG-targeting motifs, HV-DRG1, HV-DRG2, and HV-DRG3 
(Table 1, Figure 1A, and ref. 30). Fiber-modified HVs were initially 
generated on 293-fiber cells and subsequently amplified on 293 
cells to remove WF in the final HV capsid. Proper fiber modi-
fication in the genome of individual HVs was verified by DNA 
sequencing (Supplemental Figure 3B).
HV containing DRG neuron–targeting motifs efficiently and specifically 
transduces DRG neurons in vitro and in vivo. Compared with HV-WF, 
HV-KO1S* showed 100-fold lower infectivity to 293 cells (Figure 
1B), indicating that HV-KO1S* had lost its capacity to interact 
with primary docking sites on 293 cells. As the different DRG 
motif–containing HVs were engineered on a HV-KO1S* backbone, 
they also transduced 293 cells poorly (Figure 1B and Supplemen-
tal Figure 4A). In contrast, HV-DRG1–HV-DRG3 all displayed 
markedly enhanced transduction of isolated DRG neurons (Fig-
ure 1C). Interestingly, HV-DRG1 showed the highest transduction 
efficiency, followed by HV-DRG2 and HV-DRG3. Compared 
with HV-WF, HV-DRG1 showed 100-fold higher efficiency of 
DRG neuron transduction in vitro, while HV-KO1S* displayed 
minimal transduction capacity (less than 1% that of HV-WF, 
less than 0.001% that of HV-DRG1; see Supplemental Figure 4B). 
We next investigated the transduction efficiency of DRG neurons 
by the different HVs in vivo by injecting 1 × 108 viral particles 
(vp) of HVs containing dual β-gal–neo fusion protein (βgeo) and 
luciferase gene cassettes into the subarachnoid space of C57BL/6 
mice and compared the biodistribution of the fiber-modified HVs 
5 days later. X-gal staining was barely detectable in DRG of mice 
treated with HV-WF or HV-KO1S*. In contrast, transduction of 
DRG by HV-DRG1–HV-DRG3 was evident from X-gal staining 
(Figure 1D and Supplemental Figure 6C). Occasional punctate 
X-gal reaction product was detected in the root fibers leading to 
the DRG in HV-WF–treated mice. Close microscopic observation 
revealed rare X-gal–positive areas in the brains of mice treated 
with HV-WF (e.g., an X-gal–positive area was identified in the 
lateral ventricular region; Supplemental Figure 6A), but almost 
never in the brains of mice treated with other HVs. The spinal 
cord stained positive around the vector injection site and at the 
dorsal intermediate sulcus and central canal in mice treated with 
HV-WF. Although scant staining was found in the injection sites 
of mice treated with HV-DRG1–HV-DRG3, we did not observe any 
positive staining in mice treated with HV-KO1S* (Supplemental 
Figure 5 and Supplemental Figure 6B). X-gal–positive areas were 
also identified on the surface of the sciatic nerve in the HV-WF 
group, and to a much smaller extent in the HV-DRG1–HV-DRG3 
groups, but not in the KO1S* group (Supplemental Figure 6D). 
Table 1
Features of modified fiber proteins
Sequence	 aa	Position	 WF	 DRG1	 DRG2	 DRG3	 KO1S*
HSPG 91–94 KKTK GAGA GAGA GAGA GAGA
CAR 408–409 SP EA EA EA EA
Linker 542–543 None GGSGGG GGSGGG GGSGGG GGSGGG
Insert aa NA None C-SPGARAF-C C-DGPWRKM-C C-FGQKASS-C None
WF group contained Ad5 WF. All other HVs had the KO1S* backbone, which has the BspEI site (under-
line) within the 6-aa linker and modification of the HSPG binding site (KKTK; AAAAAAACCAAG) to 
GAGA (GGCGCCGGCGCC) and the CAR binding site (SP; TCTCCT) to EA (GAGGCC). The individual 
DRG homing peptides flanked by cysteine residues are shown in bold.
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We corroborated the observation based on X-gal staining pattern 
by quantifying HV-induced luciferase activity. Again, we found 
low luciferase activity in the HV-WF group in all tissues, whereas 
high luciferase activity was present almost exclusively in the DRG 
of HV-DRG1–HV-DRG3–treated animals. Transduction by HV-
DRG1 and HV-DRG2 was 100-fold higher than that by HV-WF. 
HV-DRG3 was substantially less efficient, being only 4-fold high-
er than HV-WF (Figure 1E). Luciferase activity from HV-KO1S* 
(detargeted) was negligible in all tissues. We further determined 
long-term LacZ mRNA expression induced by HV-WF and HV-
DRG1 by quantitative RT-PCR. The expression of LacZ mRNA 
decreased over time in both groups (Figure 1F). By 60 days, LacZ 
mRNA was barely detectable in the HV-WF group, but was still 
present at a substantial level in the HV-DRG1 group.
Fiber-modified HDAd vectors expressing Cre turn on GFP expression in 
DRG neurons of ROSA-GFP mice. To test whether HDAd containing 
DRG targeting motifs in the fiber transduce the intended targets, 
we used ROSA-GFP mice, in which transgenic GFP expression is 
interrupted by the stop fragment flanked by loxP sequences. Upon 
Cre-mediated excision of the stop fragment, GFP is expressed (Fig-
ure 2A). We generated HDAd expressing Cre driven by EF-1 pro-
moter using HV-WF (referred to herein as HDAd-WF-Cre) and then 
switched vector capsids by coinfection of HDAd-WF-Cre with HV-
DRG1, HV-DRG2, HV-DRG3, and HV-KO1S* (Supplemental Fig-
ure 1C and Supplemental Figure 2B). We selected the i.t. route for 
HDAd-mediated gene transfer to the DRG, because i.t. injections 
are a routine procedure in clinical practice and are associated with 
negligible side effects when performed judiciously by trained physi-
Figure 1
Transduction of DRG neurons by fiber-modified HV. (A) DRG homing peptides DRG1, DRG2, and DRG3 were inserted into the BspEI site in 
the HI loop of fiber protein. (B) Luciferase activity in 293 cells. Cells were infected with HVs at 1,000 vp/cell and were harvested 24 hours after 
infection for luciferase assay (n = 6). (C) Luciferase activity in HV-infected DRG neurons. Primary DRG neurons were infected, and luciferase 
activity was determined, as described in B. (D) LacZ expression in DRG. Fiber-modified HVs (1 × 108 vp) were injected into C57BL/6 mice 
through subarachnoid space at the lumbar level. Mice were sacrificed 5 days after HV injection and stained for LacZ expression. Arrows denote 
X-gal–positive areas at nerve portion. Scale bars: 2 mm. (E) Luciferase activities in nervous systems. Fiber-modified HVs (1 × 108 vp) were 
injected into C57BL/6 mice as described in D, and neuronal tissues were harvested 5 days after injection. (F) Long-term LacZ expression in 
DRG. Mice were treated with 1 × 108 vp HV-WF or HV-DRG1 and sacrificed at various times. LacZ mRNA in DRG was quantified by real-time 
RT-PCR and normalized to β-actin mRNA. Results are expressed relative to the day-60 HV-WF group. *P < 0.001, **P < 0.01, ***P < 0.05 versus 
WF. Note the use of log scale in B, C, E, and F.
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cians. HDAd were injected locally into the subarachnoid space, mice 
were sacrificed 5 days later, and mRNA expression was determined 
by real-time RT-PCR. The expression of Cre and GFP in different 
tissues (Figure 2, B and C) was consistent with the biodistribution 
of HV (Figure 1, C–E). HDAd-DRG1-Cre–HDAd-DRG3-Cre all 
expressed Cre and GFP 10- to 50-fold higher than HDAd-WF-Cre 
in DRG, while HDAd-KO1S*-Cre showed minimal expression. The 
Cre mRNA level was barely detectable in brain and sciatic nerve. It 
was generally low in spinal cord, in which tissue the HDAd-WF-
Cre led to the highest expression compared with the other tissues 
and other vectors tested (Figure 2B). GFP mRNA expression was 
barely detectable in all 3 sites (brain, spinal cord, and sciatic nerve; 
Figure 2C). Furthermore, very low levels of Cre and GFP mRNA 
were detected in DRG of the HDAd-WF-Cre–treated group (Fig-
ure 2, B and C). In contrast, HDAd-DRG1-Cre–HDAd-DRG3-Cre 
led to parallel high-level expression of both Cre and GFP mRNA in 
DRG of injected animals. In all cases, HDAd-KO1S*-Cre–induced 
expression of Cre and GFP was essentially undetectable. The rela-
tive mRNA levels were also reflected by the relative expression of 
Cre and GFP proteins by immunoblot analysis (Figure 2D). HDAd-
DRG1-Cre and HDAd-DRG2-Cre induced 30-fold higher protein 
levels than HDAd-WF-Cre. Similarly, GFP expression in mice treat-
ed with HDAd-DRG1-Cre or HDAd-DRG2-Cre was more than 100-
fold higher than that with HDAd-WF-Cre, while it was virtually 
undetectable in mice treated with HDAd-KO1S*-Cre (Figure 2D). 
By fluorescent microscopy, GFP fluorescence was readily detected 
Figure 2
HDAds harboring DRG neuron homing peptides transduce DRG neurons and turn on GFP expression in ROSA-GFP mice. (A) Strategy to 
evaluate targeting tissues in ROSA-GFP mice using fiber-modified HDAd expressing Cre. GFP gene expression is blocked by a STOP fragment 
flanked by loxP sequence. Upon excision of the STOP fragment by Cre, GFP is expressed. Thereby, GFP expression is dependent on HDAd-
mediated Cre gene transfer. (B and C) Cre and GFP mRNA expression in neuronal tissues. Fiber-modified HDAd expressing Cre (1 × 108 vp) 
were injected i.t. into ROSA-GFP mice. Neuronal tissues were harvested 5 days after injection, and mRNA was quantified by real-time RT-PCR. 
Results are expressed relative to the HDAd-WF-Cre–treated DRG group. HV contamination in fiber-modified HDAd, determined by real-time 
PCR, ranged from 0.0007% to 0.037%. (D) Immunoblot analysis of Cre and GFP protein expression 5 days after HDAd injection. Band intensities 
were normalized to GAPDH. Numbers below blots denote protein expression, expressed relative to HDAd-WF-Cre. (E and F) Long-term Cre and 
GFP mRNA expression in DRG. HDAd-WF-Cre or HDAd-DRG1-Cre (1 × 108 vp) were injected into ROSA-GFP mice, and Cre and GFP mRNAs 
in DRG were analyzed at the indicated time points. Results are expressed relative to the day-60 HDAd-WF-Cre group. *P < 0.05, **P < 0.01, 
***P < 0.001 versus WF, #P < 0.05, ##P < 0.01 versus KO1S*. Note the use of log scale in E and F.
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in individual neurons of DRG transduced by HDAd-DRG1-Cre and 
HDAd-DRG2-Cre (Figure 3A). HDAd-DRG3-Cre–transduced DRG 
emitted weak fluorescence; HDAd-WF-Cre also produced detect-
able but even weaker fluorescence. No fluorescence was detected in 
the KO1S* group. The proportion of GFP+ to DAPI+ neurons was 
88.1% in the HDAd-DRG1-Cre group, 67.7% in the HDAd-DRG2-
Cre group, 16.9% in the HDAd-DRG3-Cre group, and 6.3% in the 
HDAd-WF-Cre group, respectively (Figure 3B). The size distribu-
tion of GFP+ cells was generally larger in the HDAd-DRG1-Cre 
and HDAd-DRG3-Cre groups than in the HDAd-DRG2-Cre group 
(Figure 3C). A few scattered GFP+ areas were found in the brain and 
sciatic nerve of the HDAD-WF-Cre group (Supplemental Figure 7, 
A and C, arrows), while GFP+ areas were identified in the spinal cord 
at or close to the injection sites in all but the HDAD-KO1S*-Cre 
group (Supplemental Figure 7B).
HDAds produce long-term transgene expression with markedly attenu-
ated inflammatory response. Transgenes delivered by Ads, including 
HDAds, are essentially not integrated into the host genome, and 
their expression decreases with cell turnover. We compared the level 
of Cre and GFP mRNA expression in the DRG of HDAd-DRG1-
Cre– and HDAd-WF-Cre–treated groups. HDAd-WF-Cre treatment 
led to low-level expression of both at day 5, with rapid decline in 
relative expression over the next 2 months, such that 22.9% and 
14.5% of the initial day-5 mRNA levels remained at day 60 for Cre 
and GFP, respectively (Figure 2, E and F). In contrast, HDAd-DRG1-
Cre–treated DRG led to more than 100-fold higher Cre and GFP 
expression at day 5. Over the subsequent 2 months, mRNA expres-
sion diminished at a greatly reduced rate and was 23.3% for Cre 
and 18.5% for GFP mRNA at day 60. To further examine both the 
long-term transgene expression by HDAd and its effect on the host 
Figure 3
Histological analysis of GFP expression in DRG neurons after transduction with DRG-targeting HDAd vectors. (A) GFP expression in whole 
DRG tissues. Shown are images under GFP filter and bright filter. Dashed lines denote the margin of DRG tissues. (B) DRG sections with DAPI 
nuclear stain. (C) Distribution of GFP-positive DRG neurons in each 5 μm of mean diameter. Scale bars: 100 μm.
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inflammatory response, we injected βgeo-expressing HDAd and HV 
into mice (Supplemental Figure 2, A and C). We first quantitated 
LacZ mRNA expression for the 2-month period after injection (Fig-
ure 4A). Given the arbitrary setting of LacZ mRNA day-5 expression 
as 100%, for both HDAd-WF-βgeo and HDAd-DRG1-βgeo, expres-
sion gradually decreased to approximately 20% at day 60. In the 
corresponding HVs, HV-WF and HV-DRG1, the decline in mRNA 
was substantially faster, to about 0.4%–1.7% of the initial level at 
day 60. Thus, the relative stability of transgene expression depends 
on the vector (lasting substantially longer for HDAd than for HV), 
and not on the fiber type (WF versus DRG1). We note, however, 
that HDAd-DRG1-βgeo, which showed 100-fold higher initial LacZ 
expression, was still readily apparent at the end of 60 days, whereas 
HV-mediated expression was no longer evident. HDAd does not 
produce any viral proteins, and HDAd-mediated transgene expres-
sion is largely free of chronic inflammatory response. Nonetheless, 
an acute inflammatory response can happen upon HDAd or HV 
administration as a result of innate immunity. We monitored acute 
toxicity by measuring cytokines secreted into the CSF and found 
that IL-6 levels increased 3 hours after vector injection in all groups, 
but to a much lesser extent in mice treated with HDAd. However, 
IL-6 production after HDAd-KO1S*-βgeo and HDAd-DRG1-βgeo 
injection was significantly lower than that after HDAd-WF-βgeo 
injection (Figure 4B). Although IL-6 expression was still elevated 
in mice treated with HV-WF 24 hours later, it returned to a level 
similar to that of PBS treatment (Supplemental Figure 8A) in all 
other groups, which suggests that attenuation of natural tropism 
reduces Ad-associated induction of IL-6. The secretion of TNF-α 
was not influenced by detargeting (Figure 4C and Supplemental 
Figure 8B). However, the response to HDAd and HV differed mark-
edly: HV produced a robust TNF-α response that lasted at least 2 
weeks, while the response to HDAd was greatly attenuated (Figure 
4C). The kinetics of CSF IL-1β differed from those of IL-6 or TNF-α 
(Figure 4D). Importantly, PBS alone increased IL-1β 4-fold at 3 
hours after injection and returned to pretreatment level by day 
3 (Supplemental Figure 8C). The IL-1β level was elevated in all 
groups 3 hours after the vector injection. Although the increase of 
IL-1β in the HV groups was higher than the HDAd groups, the dif-
ference, especially at the early 3-hour time point, was much smaller 
than that observed for IL-6 or TNF-α.
Figure 4
Fiber-modified HDAd supports long-term transgene expression and improves safety profile. (A) Long-term expression of lacZ gene in DRG. Ad 
or HDAd vectors (1 × 108 vp) were injected into C57BL/6 wild-type mice, and DRG was isolated at the indicated time points for quantitation of 
LacZ mRNA, normalized to β-actin mRNA. Results are expressed relative to day 5. (B–D) Targeted HDAd vector induces less inflammation. 
CSF was collected at the indicated time points, and cytokines IL-6 (B), TNF-α (C), and IL-1β (D) were measured by ELISA. *P < 0.01, **P < 0.05 
versus HV-WF; #P < 0.01, ##P < 0.05 versus HDAd-WF-βgeo; ‡P < 0.001, †P < 0.01, ††P < 0.05 versus respective HV.
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A single injection of DRG-targeting HDAd expressing β-hexosaminidase 
restores enzyme activity and function of sensory neurons in a mouse model 
of Sandhoff disease. DRG neurons are involved in many neurological 
diseases that impair the structural integrity and function of sen-
sory neurons. However, few well-characterized animal models are 
available to test the effects of restoration of function in sensory 
neurons. We found that a mouse counterpart of Sandhoff disease 
in humans was a useful model for this purpose. Sandhoff disease 
is caused by mutations in the β-hexosaminidase β subunit gene 
(HEXB). Absence of this enzyme subunit leads to defective GM2 
Figure 5
Gene therapy for a mouse model of Sandhoff disease. (A) Hexb gene expression in neuronal tissues. Various fiber-modified HDAd vectors 
(1 × 108 vp) were injected into Hexb–/– mice through subarachnoid space at the lumbar level, and neuronal tissues were isolated for extraction 
of cellular RNA 8 weeks after injection. Hexb mRNA was quantified by real-time RT-PCR, and expression was calculated relative to that in the 
brains of wild-type mice. Undetectable expression levels are denoted by “0.” (B–D) Hexosaminidase activities in nervous tissues from wild-type 
and Hexb–/– mice with fiber-modified HDAd vector injection. (B) Total hexosaminidase (HEX). (C) Hexa. (D) Hexb (calculated by subtracting 
Hexa activity from total hexosaminidase activity). (E) Immunofluorescence (IF) for Hexb protein in DRG. (F) In situ staining for hexosaminidase 
activity. Nuclei were stained with methyl green. Arrows indicate weak positive staining in neurons. Scale bars: 20 μm. *P < 0.001; **P < 0.01, 
***P < 0.05. #P < 0.01, ##P < 0.05 versus empty vector–treated Hexb–/–.
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ganglioside degradation and massive accumulation of the ganglio-
side and other substrates in the lysosomes of neurons. The mouse 
model for this disease, Hexb–/– mice, has previously been shown 
to develop progressive impairment of motor function (31). Here 
we found that the DRG of these mice exhibited the typical histo-
pathological changes of GM2 gangliosidosis; furthermore, the 
animals also displayed abnormal sensory nerve conduction veloc-
ity (SNCV) and action potential, objective measurements that can 
Figure 6
DRG-targeted Hexb expres-
sion rescues sensory neuronal 
responses in Hexb–/– mice. 
Electrophysiological studies 
and behavior tests were per-
formed at 4 and 8 weeks after 
treatment. (A) SNCV was mea-
sured on sural nerve. (B) SNAP 
was recorded in proximal site 
after stimulation in the distal 
site at ankle joint. (C) First con-
tact time. (D) Adhesive removal 
test. Data are expressed as 
mean ± SD. n = 8 (empty vector); 
9 (WF-Hexb); 11 (DRG1-Hexb); 
12 (wild type). (E) Nissl stain. 
(F) PAS stain with hematoxy-
lin for nuclear stain. Enlarged 
views of boxed regions are 
shown below. Arrows indicate 
granular formations in neurons. 
Scale bars: 20 μm. *P < 0.01, 
**P < 0.05. #P < 0.01, ##P < 0.05 
versus wild type.
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be used to gauge the severity of the disease. We investigated the 
effect of DRG neuron–targeted enzyme replacement on the abnor-
mal histology and sensory neuronal impairment in Hexb–/– mice. 
We injected 1 × 108 vp of HDAd vectors expressing Hexb driven by 
the EF-1 promoter into the subarachnoid space of Hexb–/– mice at 
4 weeks of age and measured mRNA level and enzyme activity in 
nerve tissues 8 weeks later. An empty vector was used as control. In 
wild-type mice, all neural tissues expressed Hexb mRNA, empty vec-
tor–treated Hexb–/– mice displayed no detectable Hexb mRNA, while 
Hexb–/– mice treated with HDAd-DRG1-Hexb (referred to herein as 
DRG1-Hexb) expressed Hexb mRNA almost exclusively in DRG, at a 
level that was significantly higher than that of wild-type mice (Fig-
ure 5A). The HDAd-WF-Hexb produced Hexb mRNA in brain and 
spinal cord at a level that was substantially lower than that in wild-
type mice. Hexa is a heterodimer of α and β subunits, and Hexb is 
a homodimer of hexosaminidase β subunits. Expression of Hexb 
rescued both Hexa and Hexb activities in Hexb–/– mice. After treat-
ment, total hexosaminidase and Hexa activities in DRG increased 
to 75%–76% those in wild-type mice (Figure 5, B and C), and Hexb 
activity was similar to wild-type levels (Figure 5D). The small dis-
crepancies between mRNA level and enzyme activities were probably 
attributed to the suboptimal ratio of the 2 subunits. As in wild-type 
mice, Hexb protein expression in DRG neurons in DRG1-Hexb–
treated Hexb–/– mice was confirmed by immunofluorescence, which 
showed that most DRG neurons were positive for Hexb (Figure 5E). 
In contrast, immunofluorescence staining was totally absent in the 
empty vector group and barely detectable in the WF-Hexb–treated 
DRG (Figure 5E). Histochemically, Hex enzyme activity was revealed 
in the section in situ by a purple-brown coloration resulting from 
diazonium coupling between fast Garnet GBC and the products 
catalyzed from naphthol-AS-BI-D-N-acetyl-β-glucosaminide by 
hexosaminidase. In agreement with our enzyme activity data, the 
histochemical stain in DRG1-Hexb–treated mice was present at a 
level similar to that in wild-type mice, while mice treated with WF-
Hexb exhibited much lower coupling and those with the empty vec-
tor displayed no evident coupling (Figure 5F). Sandhoff disease is a 
serious gangliosidosis that affects both the central and the periph-
eral nervous systems and is associated with a much shorter lifespan 
— we euthanized mice at 16–20 weeks of age because of severe debili-
tating motor dysfunction. Although DRG1-Hexb treatment did not 
extend the time until euthanasia, progression of objective measures 
of DRG function was markedly improved by the treatment. The 
DRG1-Hexb group maintained intact SNCV at a normal level 4 and 
8 weeks after treatment, while mice treated with empty vector or 
WF-Hexb exhibited significantly impaired SNCV (Figure 6A). Unlike 
the intact SNCV at 8 weeks in mice treated with DRG1-Hexb, the 
motor nerve conduction velocity (MNCV) deteriorated at similar 
rates in all treatment groups compared with untreated wild-type 
controls (Supplemental Figure 9A). Sensory nerve action potential 
(SNAP) deteriorated markedly in empty vector–treated Hexb–/– mice 
at 8 weeks after treatment (12 weeks of age). The DRG1-Hexb treat-
ment group maintained its SNAP at the same level between 4 and 
8 weeks, whereas WF-Hexb treatment failed to slow the progressive 
impairment of SNAP in Hexb–/– mice (Figure 6B). In contrast, none 
of the different HDAd treatments could slow the deterioration in 
compound muscle action potential (CMAP; Supplemental Figure 
9B). We performed a functional neurological behavior test by mea-
suring the time needed for the mice to remove an adhesive tape from 
their hind paw (36). In Hexb–/– mice, the time of first contact for 
tape removal increased progressively with age. Treatment with WF-
Hexb had no effect on first contact time, while DRG1-Hexb treat-
ment significantly shortened this time and slowed deterioration in 
this parameter at 4 and 8 weeks (Figure 6C). The time required for 
successful tape removal was also improved by DRG1-Hexb, but not 
WF-Hexb, at 4 weeks; however, the beneficial effect of the treatment 
on this parameter, which depends also on relatively intact motor 
function, disappeared after 8 weeks (Figure 6D). We investigated 
the structural integrity of DRG neurons histologically 8 weeks after 
vector injection. By Nissl staining, DRG neurons in Hexb–/– mice 
treated with DRG1-Hexb were similar to those in wild-type mice, 
although the staining in Hexb–/– mice was slightly less intense than 
in wild-type mice (Figure 6E). This is consistent with the enzyme 
histochemistry results described above. In contrast, DRG neurons 
treated with empty vector or WF-Hexb showed much lighter stain-
ing (Figure 6E), which suggests neuronal degeneration. In periodic 
acid–Schiff (PAS) staining, granular formation (Figure 6F, arrows) 
was evident in many DRG neurons in mice treated with the empty 
or WF-Hexb vector, while such accumulation of carbohydrate mac-
romolecules was not detected in the DRG1-Hexb–treated and wild-
type groups (Figure 6F).
Discussion
Sensory neuronopathies affecting DRG neurons that manifest as 
pain, hypo- or hyperalgesia, and anesthesia or ataxia can be caused 
by genetic, nutritional, metabolic, inflammatory, or neoplastic 
processes. A strategy that enables the efficient delivery of thera-
peutic transgenes specifically to DRG neurons would represent a 
significant advance in the treatment of DRG neuronal disorders, 
because therapeutic measures aimed only at the underlying disease 
process often fail to reverse the neuronopathy (1, 2).
Our strategy to address this problem was to engineer fiber-
modified HDAds that specifically target DRG neurons in vivo. We 
selected HDAd as the vector because of its large capacity, negli-
gible toxicity, and prolonged transgene expression in the absence 
of integration, which minimizes its potential tumorigenic effects 
(37). The target tissue specificity of an HDAd is determined by the 
specificity of the HV. By using a HV ablated for binding to primary 
attachment receptors in the fiber (KO1S* mutation) as a platform, 
we inserted into the HI loop DRG neuron–homing peptides iso-
lated by phage display and biopanning (30). In a previous study, 
we showed that the presence of the S* mutation at the putative 
HSPG binding region causes fibers defective at a postinternaliza-
tion step that lead to poor cellular transduction (34). However, 
this problem was overcome by incorporating peptide ligands that 
retargeted the fiber in a manner that allowed for efficient internal-
ization and nuclear trafficking. When we injected the Ad into the 
subarachnoid space, we found that modified Ad was also detar-
geted from DRG neurons in vivo. For subgroup C Ad, including 
Ad5, infection of Ad in vitro occurs first by direct attachment of 
the fiber to the CAR, then by internalization through αV integrin 
via the RGD motif of penton bases or by interaction with HSPG 
(38). However, i.v. Ad5 directly binds to coagulation factors via 
interaction between the FX Gla domain and hypervariable regions 
of the Ad5 hexon surface (22, 23) and is subsequently internalized 
by binding to LRP and/or HSPG in the liver (21, 24). Koizumi et 
al. have reported that Ads ablated for binding to CAR, αV integrin, 
and HSPG within the FG loop in the fiber knob, as well as Ads 
that carry a mutation of the AB loop and substitution of the fiber 
shaft derived from Ad type 35, have markedly reduced tropism to 
the liver; the modifications also attenuate toxicity, as defined by 
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IL-6 secretory response after i.v. injection (25). We left the penton 
and the RGD motif intact, as the RGD motif was thought to be 
needed for endocytosis and endosomal escape (39, 40). We found 
that ablation for CAR and HSPG was sufficient to blunt natural 
tropism. The favorable result obtained in this investigation was, at 
least in part, due to the direct subarachnoid delivery of the vector, 
a routine procedure in clinical practice that also eliminates any 
direct interaction of Ad with blood components. Indeed, this is the 
first demonstration to our knowledge of efficacy with an in vivo 
HDAd-targeted gene delivery approach.
Chronic toxicity associated with early-generation Ads has 
been largely eliminated in HDAd; however, the acute inflamma-
tory response caused by innate immunity against capsid proteins 
was reported to be similar among the different types of Ad when 
administered i.v. (41). In the current study, we found markedly 
reduced IL-6 and TNF-α levels after i.t. HDAd. It is intriguing 
that the IL-1β response was not greatly attenuated by the HDAds 
compared with the HVs. An increase in IL-1β is an early response 
to both Ad and HDAd (41) and is considered to be upstream to 
IL-6 and TNF-α. In contrast to i.v. administration, i.t. injection 
of HDAd has previously been reported to invoke neither systemic 
or local toxicity nor a CNS-specific immune reaction (42). The 
low toxicity found in the present study may be, at least in part, 
due to the presence of few immune cells in CSF. Furthermore, 
the immune response against HDAd might be different between 
systemic and i.t. injection. Recent reports have shown that the 
interaction between Ad DNA and TLRs leads to an inflammatory 
response by the host (reviewed in ref. 43). TLR9 recognizes dou-
ble-stranded unmethylated CpG DNA, and the response of TLR9 
to DNA of mammalian origin may be different from that to viral 
DNA. The difference in vector genome between HV and HDAd 
and types of innate immune cells present in the circulation or in 
the spinal fluid could explain the difference in the host response 
to the 2 types of vectors. In addition, we found that use of detar-
geted HDAd-KO1S*-βgeo and HDAd-DRG1-βgeo, which is also 
based on KO1S*, was associated with a 2-fold reduction of IL-6 
at 3 and 24 hours after vector injection, an observation consistent 
with previous reports showing attenuated cytokine response by Ad 
detargeted for natural receptors (25).
We tested 3 peptide ligands for their ability to target DRG 
neurons. DRG1- and DRG3-targeted vectors tended to bind to 
smaller size neurons than DRG2-targeted vectors. This result 
was consistent with our previous report, although the surface 
molecules interacting with these peptides have not been identi-
fied (30). HVs containing these peptide ligands increased the 
efficiency of transduction of DRG neurons in vitro as well as in 
vivo (Figure 2). DRG1 was the most potent, and transduction of 
DRG neurons by HV-DRG1 was greater than 100-fold more effi-
cient than transduction by HV-WF. This DRG-targeting HV had a 
profound effect on transgene expression. LacZ expression induced 
by HV-DRG1 at day 60 was still maintained at a level similar to 
that induced by HV-WF at day 5. Despite enhanced transduction 
efficiency of the targeting vector, there was no apparent effect of 
targeting on decay of transgene expression (Figure 4A). This is 
not unexpected, however; although tissue or cell targeting plays 
an important role in efficient transduction, it does not influence 
intracellular processing or degradation of vector chromosome. 
Phage display is a powerful technique to identify homing peptides 
to specific in vivo molecular zip codes. DRG1 appears to sup-
port vector internalization and endosome escape, which does not 
always happen (44). Phage is a small molecule compared with Ad, 
and the access of bulky Ad particles could be hampered by physi-
cal and biological barriers (44). In fact, we found that although 
i.t. HV-DRG1 efficiently transduced DRG neurons, i.v. HV-DRG1 
failed to transduce DRG neurons in vivo (data not shown).
Despite the many human diseases affecting DRG neurons, few 
mouse models of pure sensory neuron dysfunction are available. 
We decided to use Hexb–/– mice, which exhibit global neurologi-
cal impairment at 3 months followed by ataxia, bradykinesia, 
and impaired motor activity and balance. By 18 weeks, hind-limb 
movement is lost, and they die before 20 weeks (31, 32). As in 
vivo measurements of sensory function have not to our knowl-
edge been reported in this mouse model, we first documented 
the occurrence of peripheral sensory impairment in this disor-
der using sensory nerve conduction studies and mixed sensory/
motor function (i.e., tape removal) tests (Figure 6, C and D). A 
single injection of DRG1-Hexb by lumbar puncture into the CSF 
increased Hex activity in DRG neurons and restored peripheral 
sensory function, but not motor neuron function, in Hexb–/– mice. 
In histological analysis, Hexb-immunoreactive protein was readily 
detected in DRG neurons of mice treated with DRG1-Hexb but not 
with WF-Hexb. Very little PAS-positive granular formation in the 
cell body, which represents ganglioside accumulation, was seen in 
the DRG1-Hexb–treated mice. Nissl stain was strongly positive in 
the DRG1-Hexb group, similar to that seen in wild-type mice. It 
is important to note that DRG1-Hexb treatment conferred pro-
tection to sensory neuron function but had no detectable effect 
on motor nerve function. When we assessed nerve function by the 
tape removal test, deterioration in first contact time was signifi-
cantly improved by the treatment at both 4 and 8 weeks, because 
sensory function was dominant in this behavior test. In contrast, 
the tape removal time, determined by a combination of sensory 
and motor functions, was partially corrected at 4 weeks, but not 
at 8 weeks. Despite a marked improvement in SNCV, the behavior 
tests were still quite abnormal, because performance in these tests 
requires the presence of intact peripheral and central nervous sys-
tems, and our treatment had no effect on the latter. Therefore, use 
of the Hexb–/– mice enabled us to show that DRG neuron–targeted 
gene therapy specifically restored DRG function without affecting 
motor nerve, spinal cord, or brain function.
There are many potential clinical applications of the treatment 
strategy that we developed in this investigation. Neuropathic pain 
occurs commonly among patients with various metabolic and 
inflammatory disorders. For example, diabetic neuropathy is the 
most common chronic complication of diabetes, affecting millions 
of people in the United States (45). Many of these individuals expe-
rience neuropathic pain caused by sensory neuron dysfunction (6). 
Patients with ganglionopathies caused by autoimmune diseases or 
drug toxicities also commonly experience severe neuropathic pain 
(2). Treatment of these and other sensory neuronopathies by i.t. 
DRG-targeting HDAds that express neurotrophic factors or anal-
gesic peptides may become a new therapeutic option in the future. 
It has previously been reported that the immune response to for-
eign material injected i.t. is attenuated (18, 42), which may allow 
for the repeat administration of HDAd via this route for repeated 
treatments. We note that HDAd can be administered repeatedly 
even when it is given by the i.v. route, as long as we use HVs of 
different serotypes (33, 46). Finally, the nonintegrating nature of 
HDAd is an advantage in that it minimizes the chance of genotox-
icity and induced tumorigenesis (37).
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In this study, we developed a strategy to produce HDAds that 
specifically target DRG neurons. One advantage of this approach 
is that HDAds expressing a therapeutic gene made by a generic HV 
could be retargeted to tissues or cell types of interest by amplifi-
cation with HVs containing targeting ligands. HDAds and fiber-
modified HVs were separately produced and combined only at 
the final amplification step. It is noteworthy that novel targeting 
peptides are being identified by multiple laboratories (47), and the 
repository of targeting HVs will expand rapidly, which will allow 
us to customize HDAd delivery to treat specific diseases and organ 
systems. Clinical trials using early-generation Ads have been ongo-
ing for years (48, 49). The development of the strategy described 
herein, using the much more versatile and far less toxic HDAd, 
should facilitate its possible application in clinical trials for DRG 
neuronopathies in the near future.
Methods
Cell culture. To generate 293-fiber cells, we used lentiviral vector–mediated 
gene transfer. Ad5 fiber was subcloned by PCR from AdEasy vector using 
the following primers: 5′ upstream, 5′-GGATCCGCCACCATGAAGC-
GCGCAAGACCGTC-3′; 3′ downstream, 5′-GCGGCCGCTTATTCTT-
GGGCAATGTATG-3′. They contained artificial cloning sites (underline) 
and the Kozak sequence (bold). The Ad5 fiber cDNA was then subcloned 
into the pHIV-EF-1-puro, a first-generation self-inactivating vector modi-
fied from pHIV-AP (50). LV-Ad5 fiber was produced by cotransfection of 
LV shuttle vector and pME-VSVG into 293T cells by the standard calcium 
phosphate precipitation method (Supplemental Figure 3A). The 293-fiber 
cells were established by selection on puromycin (1 μg/ml). We maintained 
293, 293-fiber, and 293Cre66 cells in α-MEM supplemented with 10% FBS 
and antibiotic-antimicotics (Invitrogen). Puromycin (1 μg/ml) and G418 
(0.8 mg/ml) were included in the media for 293-fiber and 293Cre66 cells, 
respectively. DRG neurons were isolated from C57BL/6 mice 1 day before 
experiments and cultured under F-12 with 10% FBS, as previous described 
(30). Infection was performed in nonserum media at 37°C for 30–60 min-
utes in a CO2 incubator.
Construction of fiber-modified first-generation HV. To construct fiber-modi-
fied HV (Supplemental Figure 1A) using AdEasy system (Stratagene), a 
2-kb fragment containing 1.7-kb NdeI/PmeI fragment coding for Ad5 
fiber was first subcloned into pCR2.1-TOPO (Invitrogen) by PCR using 
pDV153-KO1S* as a template, generating pCR2.1-fiber-KO1S*. A deriva-
tive of pDV137, pDV153-KO1S* harbors the S* mutation of the putative 
HSPG-binding region, the KO1 mutation, and the unique BspEI site in the 
HI loop (Table 1, Figure 1A, and ref. 34). Next, 3 peptide ligands targeting 
DRG neurons isolated by biopanning of phage display (30) were subcloned 
into the BspEI site of pCR2.1-fiber-KO1S*, resulting in pCR2.1-DRG1, 
-DRG2, and -DRG3. The 1.7-kb NdeI/PmeI fragment was excised from 
these 3 vectors and pCR2.1-fiber-KO1S*, then subcloned into pDV153-
KO1S* vector. The 7-kb SpeI/PacI fragment from these 4 clones were sub-
cloned into pAdEasy-1 vector (Stratagene). To make fiber-modified HV, we 
modified pShuttle (Stratagene) to have the packaging signal (φ) flanked by 
loxP sites with the MluI site downstream of the second loxP site for clon-
ing purposes (pShuttle-loxP-φ-loxP). To insert 2 reporter genes in HV, we 
first subcloned both the 5.2-kb βgeo cassette and the 2.2-kb BamHI/BglII 
fragment of RLCMV (Promega) containing an Rluc expression cassette into 
pLPBL-1. The resulting dual gene expression cassette was excised by AscI 
digestion and subcloned into the MluI site of pShuttle-loxP-φ-loxP, creating 
pShuttle-loxP-φ-loxP-βgeo-RLCMV. HV plasmids were generated by homol-
ogous recombination in BJ5183 cells (Stratagene). HV-DRG1, HV-DRG2, 
HV-DRG3, and HV-KO1S* were produced by transfection into 293-fiber 
cells. HV-WF was produced on 293 cells. After production of HVs, we tested 
the excision of the packaging signal by 293Cre66 cells. Infection of 293Cre66 
with HVs removed the packaging signal, resulting in a 262-bp PCR product 
instead of the 460-bp product from the intact HV. The excision of the pack-
aging signal was also confirmed by DNA sequence analysis.
Construction of HDAd vectors. The cDNA of Cre recombinase was cloned 
by PCR using pBS185 vector (Invitrogen) as template and the following 
PCR primers: 5′ upstream, 5′-TTAATTAAGCCACCATGTCCAATT-
TACTGACCGTACAC-3′; 3′ downstream, 5′-GCGGCCGCCTAATCGC-
CATCTTCCAGCAG-3′. They contained artificial cloning sites (underline) 
and the Kozak sequence (bold). The Hexb cDNA was cloned from C57BL/6 
mouse brain into pCR2.1-TOPO (Invitrogen) by RT-PCR using the follow-
ing primers: 5′ upstream, 5′-ATGCCGCAGTCCCCGCGTA-3′; 3′ down-
stream, 5′-CTGGAATGCTGTAGACGTCTGTC-3′. These cDNAs were sub-
cloned into pBOS vector that contains EF-1 promoter and rabbit β-globin 
polyadenylation signal on pLPBL-1 backbone. These expression cassettes 
and βgeo-RLCMV described above were excised by AscI digestion and then 
subcloned into pΔ28 vectors (51). All HDAd vectors were first made by a 
previously published method (37) using HV-WF and 293Cre66 cells (Sup-
plemental Figure 1B). Fiber-modified HDAd vectors were made by coinfec-
tion of HDAd vector and fiber-modified HV, as outlined in Supplemental 
Figure 1. The titer of targeting-HDAd was determined by DNA concentra-
tion from purified vector solution (37). HV contamination in HDAds was 
determined by real-time PCR using the following primers: HV 5′ upstream, 
5′-GACCATCAATCTTGACGACC-3′; HV 3′ downstream, 5′-ATGTC-
GCTTTCCAGAACCC-3′; HDAd 5′ upstream, 5′-CCCATCTCCTTCATCA-
CATCTC-3′; HDAd 3′ downstream, 5′-TCACTCCAGCCTCAACATCC-3′. 
HV contamination was less than 0.05% in all preparations.
Mice. Male 8- to 12-week-old C57BL/6, B6;129-Gt (ROSA)26Sortm2Sho/J 
(Rosa-GFP), and Hexb+/– mice, a model of Sandhoff disease, were purchased 
from The Jackson Laboratory. Homozygous Hexb–/– and wild-type Hexb+/+ 
mice were generated by mating Hexb+/– mice, and littermates were used. 
Genotyping was carried out according to the protocols of The Jackson Lab-
oratory. All animals were housed, fed water and mouse chow ad libitum, 
and maintained under a 12-hour light/12-hour dark cycle. All experiments 
were performed according to protocols reviewed and approved by the Insti-
tutional Animal Care and Usage Committee at Baylor College of Medicine.
Luciferase assay in vitro and in vivo. For in vitro studies, we plated 293 cells 
and isolated DRG neurons from C57BL/6 mice 1 day before infection, and 
infected them with HVs at 1,000 vp/cell. The next day, cells were harvested 
in a lysis buffer supplied with the luciferase assay kit (Promega), and the 
lysates were assayed for luciferase activity per the manufacturer’s protocol. 
For in vivo studies, we injected 1 × 108 vp of each vector into mice through 
subarachnoid space at the lumbar level. Mice were euthanized 5 days after 
vector treatment, and brain, spinal cord, DRG, and sciatic nerve were iso-
lated. Tissues were homogenized with lysis buffer, and the supernatants 
were assayed for luciferase activity.
X-gal staining of cells and nervous tissues. For in vitro studies, cells were fixed 
with fixation solution supplied in β-gal staining kit (Invitrogen) 1 day after 
infection and incubated with X-gal per the manufacturer’s protocol. For in 
vivo studies, mice were transcardiacally fixed with 4% paraformaldehyde 
5 days after vector injection, and isolated nervous tissues were incubated 
with X-gal for 4 hours. We observed all tissues under standard microscope 
and stereomicroscope. Several pictures for brain and spinal cord were com-
bined to show the whole central nervous system. Subsequently, 10-μm-
thick cryosections were prepared.
Quantitative RT-PCR. Total cellular RNA was extracted by TRIzol 
(Invitrogen) and treated with DNase I digestion. After reverse transcrip-
tion using oligo dT, mRNA was quantified by real-time PCR using iQ 
SYBR Green Supermix (Bio-Rad). The following primers were used: LacZ 
5′ upstream, 5′-GTTGCAGTGCACGGCAGATACACTTGCTGA-3′; LacZ 3′ 
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downstream, 5′-GCCACTGGTGGGCCATAATTCAATTCGC-3′; Cre recom-
binase 5′ upstream, 5′-GCATTACCGGTCGATGCAACGAGTGATGAG-3′; 
Cre recombinase 3′ downstream, 5′-GAGTGAACGAACCTGGTCGAAAT-
CAGTGCG-3′; GFP 5′ upstream, 5′-GCACGACTTCTTCAAGTCCGC-
CATGC-3′; GFP 3′ downstream, 5′-GCGGATCTTGAAGTTCACCTTGAT-
GCC-3′; Hexb 5′ upstream, 5′-ACAGTTGCAGAAGCTCCTGGT-3′; Hexb 3′ 
downstream, 5′-CCTCTATGAGGGAATCTTGGAG-3′; β-actin 5′ upstream, 
5′-GACGGCCAGGTCATCACTAT-3′; β-actin 3′ downstream, 5′-CTTCTG-
CATCCTGTCAGCAA-3′. Detection was carried out with Mx3000P QPCR 
system (Stratagene), and results were analyzed by MxProQPCR software 
(version 4.1.0.0; Stratagene). All data were normalized to β-actin values.
Immunoblots. DRG and 293-fiber cells were lysed with RIPA buffer 
(150 mm NaCl, 2 mm EDTA, 1% Nonidet P-40, 1% sodium deoxycholate, 
0.1% SDS, 50 mm NaF, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 1 mm 
phenylmethylsulfonyl fluoride, and 20 mm Tris-HCl buffer, pH 7.4) and 
were centrifuged at 12,000 g for 20 minutes at 4°C to collect the superna-
tant. Proteins (20 μg) were separated by 7.5%–15% SDS-PAGE and trans-
ferred to a polyvinylidene difluoride filter (Immobilon Millipore). The blots 
were incubated overnight at 4°C with rabbit anti-Cre antibody (1:1,000; 
Novagen), mouse monoclonal anti-GFP antibody (1:1,000; BD Biosciences 
— Clontech), or anti-Ad fiber (1:1,000; ab3233; Abcam). Immunoreactive 
proteins were detected by enhanced chemiluminescence (PIERCE Biotech-
nology) after incubation with either horseradish peroxidase–conjugated 
anti-rabbit Ig or anti-mouse Ig (1:2,000; Bio-Rad).
ELISA for cytokines in CSF. CSF was collected from cistern magna at 3 and 
24 hours as well as 3, 7, and 14 days after vector injection. IL-1β, IL-6, and 
TNF-α levels were determined using an ELISA kit (eBioscience).
Hexosaminidase enzyme assay. Total β-hexosaminidase activity was mea-
sured using 4-methylumbelliferyl-2-acetamido-2-deoxy-β-D-glucopyrano-
side (4-MUG; Sigma-Aldrich) as the substrate. Hexa activity was assayed 
using 4-methylumbelliferyl-6-sulfo-2-acetamido-2-deoxy-β-D-glucopyran-
oside (4-MUGS; Calbiochem). Hexb activity was determined by subtracting 
Hexa activity from total hexosaminidase activity (52). Enzyme activity was 
expressed as nmol/mg protein/h.
Histological analysis of GFP expression in ROSA-GFP mice. For GFP expres-
sion analysis, nervous tissues were directly observed under fluorescent 
microscope after dissections. The 10-μm cryosections were prepared from 
DRG and mounted with VECTASHIELD mounting medium with DAPI 
(Vector Laboratories).
Histological analysis of Hexb–/– mice. Mice were perfused transcardially with 
cold saline followed by 4% paraformaldehyde, 0.05% glutaraldehyde, 0.5% 
picric acid, and 0.01 M phosphate buffer (pH 7.4) solution. L1–L5 DRG 
tissues were removed, and 10-μm-thick cryosections were incubated with 
goat anti-Hexb antibody (1:100; Santa Cruz Biotechnology Inc.) overnight 
at 4°C. The next day, sections were incubated with rhodamine-labeled don-
key anti-goat IgG and mounted with VECTASHIELD mounting medium 
with DAPI (Vector Laboratories). Other sections from vector-treated mice 
were also used for PAS (PAS staining system; Sigma-Aldrich) and Nissl 
stain with cresyl violet (Sigma-Aldrich). For enzymatic histochemical anal-
ysis of hexosaminidase, DRG were immersed in Baker fixative solution (4% 
paraformaldehyde and 1% anhydrous calcium chloride, pH 7.2) for 1 hour 
at 4°C, then immersed into gum-sucrose solution (14% antiseptic thymol, 
0.14% gum arabic, 1.25 M saccharose) for 24 hours at 4°C. Cryosections 
(10 μm) were incubated in working solution containing 0.5 mM naphthol-
AS-BI-D-N-acetyl-β-glucosaminide (Sigma-Aldrich) and 3.6 mM Fast Gar-
net GBC sulfate salt (Sigma-Aldrich) at pH 5.2 for 30 minutes at 37°C and 
then counterstained with 1% methyl green for nuclei.
Electrophysiological studies and behavior tests. Nerve conduction studies were 
performed with CADWELL SIERRA 6200A (Cadwell Laboratories) under 
anesthetization at temperatures from 30°C to 32°C. The motor nerve con-
duction study was performed in the sciatic nerves as described previously 
(53). For sensory nerve conduction studies, sural nerves were stimulated 
in the distal site at the ankle joint level and were recorded in a proximal 
site (53). Adhesive removal tests were performed as neurological behavior 
tests. Small adhesive stimuli (0.25-inch round Avery adhesive labels) were 
placed on the hind paw of the mouse, and the time to make contact and 
remove the sticker was recorded. To remove the stickers, animals would use 
both fore limbs toward their feet and swipe off the stimulus with both fore 
paws. Each mouse received 3 trials and had an intertrial interval of at least 
3 minutes. All testing was performed in the animal’s home cage (36).
Statistics. All data are expressed as mean ± SD. All in vitro experiments 
were performed in triplicate in at least 3 independent experiments. In vivo 
analyses were performed using 5 mice per group, unless otherwise specified. 
Student’s unpaired 2-tailed t test was used to calculate statistical significance 
for differences between 2 groups. For multiple data sets, 1-way ANOVA and 
Scheffe’s test were used. A P value less than 0.05 was considered significant.
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